231 related articles for article (PubMed ID: 29360073)
1. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
2. Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Dika IE; Abou-Alfa GK
Clin Mol Hepatol; 2017 Dec; 23(4):273-279. PubMed ID: 29151326
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
[TBL] [Abstract][Full Text] [Related]
4. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Weinmann A; Galle PR
Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
[TBL] [Abstract][Full Text] [Related]
8. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
Villarruel-Melquiades F; Mendoza-Garrido ME; García-Cuellar CM; Sánchez-Pérez Y; Pérez-Carreón JI; Camacho J
World J Gastroenterol; 2023 May; 29(17):2571-2599. PubMed ID: 37213397
[TBL] [Abstract][Full Text] [Related]
9. The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma.
Kim BK
Gut Liver; 2024 Jan; 18(1):3-4. PubMed ID: 38221815
[No Abstract] [Full Text] [Related]
10. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Jiang Y; Tu X; Zhang X; Liao H; Han S; Jiang W; Zheng Y; Zhao P; Tong Z; Fu Q; Qi Q; Shen J; Zhong L; Pan Y; Fang W
Support Care Cancer; 2020 Nov; 28(11):5569-5579. PubMed ID: 32361828
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in the Treatment of HCC.
Donisi C; Puzzoni M; Ziranu P; Lai E; Mariani S; Saba G; Impera V; Dubois M; Persano M; Migliari M; Pretta A; Liscia N; Astara G; Scartozzi M
Front Oncol; 2020; 10():601240. PubMed ID: 33585218
[TBL] [Abstract][Full Text] [Related]
13. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
Roy P; Parthasarathy KM
J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of drug resistance in HCC.
Ladd AD; Duarte S; Sahin I; Zarrinpar A
Hepatology; 2024 Apr; 79(4):926-940. PubMed ID: 36680397
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials.
Gamboa AC; Kooby DA; Maithel SK; Gamblin TC
J Surg Oncol; 2024 Jan; 129(1):63-70. PubMed ID: 38059310
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.
Gao H; Chang RZ; Chen XP; Zhang WG; Zhang B; Luo X; Ding ZY
Front Immunol; 2023; 14():1274449. PubMed ID: 37869012
[TBL] [Abstract][Full Text] [Related]
17. Implications of Immunotherapy in Hepatobiliary Tumors.
Gottlieb A; Best J; Canbay A
Visc Med; 2019 Mar; 35(1):18-26. PubMed ID: 31312646
[TBL] [Abstract][Full Text] [Related]
18. Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.
Wei H; Dong C; Li X
J Clin Transl Hepatol; 2024 Apr; 12(4):389-405. PubMed ID: 38638377
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Ho WJ; Zhu Q; Durham J; Popovic A; Xavier S; Leatherman J; Mohan A; Mo G; Zhang S; Gross N; Charmsaz S; Lin D; Quong D; Wilt B; Kamel IR; Weiss M; Philosophe B; Burkhart R; Burns WR; Shubert C; Ejaz A; He J; Deshpande A; Danilova L; Stein-O'Brien G; Sugar EA; Laheru DA; Anders RA; Fertig EJ; Jaffee EM; Yarchoan M
Nat Cancer; 2021 Sep; 2(9):891-903. PubMed ID: 34796337
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.
van Doorn DJ; Takkenberg RB; Klümpen HJ
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33374927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
